Neurocrine Biosciences announced positive results from the company’s Phase III KINECT-HD study evaluating the efficacy of valbenazine in the treatment of chorea associated with Huntington’s Disease (HD).
Capricor Therapeutics Inc. put on hold a clinical trial of the company’s experimental drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.
Neurocrine Biosciences Inc. announced today that the U.S. Food and Drug Administration approved an 80-mg Ingrezza (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia.
Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.
The U.S. FDA approved Neurocrine Biosciences Inc.’s drug to treat tardive dyskinesia, an uncontrolled movement side effect of antipsychotic medications.
Teva finally won approval from the U.S. FDA for Austedo, a treatment for chorea associated with Huntington’s disease.